巨子生物(02367)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02367 巨子生物

未开盘 04-22 16:08:12

76.650

+4.550

+6.31%

最高76.900	最低72.500	成交量1,063万
今开72.500	昨收72.100	日振幅6.10%
总市值794.09亿	流通市值794.09亿	总股本10.36亿
成交额8.00亿	换手率1.03%	流通股本10.36亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02367","market":"HK","secType":"STK","nameCN":"巨子生物","latestPrice":76.65,"timestamp":1745309292017,"preClose":72.1,"halted":0,"volume":10634717,"delay":0,"floatShares":1036000000,"shares":1036000000,"eps":2.2287785231142796,"marketStatus":"未开盘","change":4.55,"latestTime":"04-22 16:08:12","open":72.5,"high":76.9,"low":72.5,"amount":800113734,"amplitude":0.061026,"askPrice":76.65,"askSize":800,"bidPrice":76.6,"bidSize":8200,"shortable":3,"etf":0,"ttmEps":2.18596125160004,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1745371800000},"marketStatusCode":0,"adr":0,"listingDate":1667491200000,"exchange":"SEHK","adjPreClose":72.1,"dividendRate":0.012655,"openAndCloseTimeList":[[1745285400000,1745294400000],[1745298000000,1745308800000]],"volumeRatio":0.5693917049310795,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02367","defaultTab":"news","newsList":[{"id":"2529316728","title":"巨子生物盘中涨超5% 陕西省药监局通报多批次可复美产品均未检出EGF","url":"https://stock-news.laohu8.com/highlight/detail?id=2529316728","media":"新浪网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529316728?lang=zh_cn&edition=full","pubTime":"2025-04-22 11:48","pubTimestamp":1745293698,"startTime":"0","endTime":"0","summary":"巨子生物盘中涨超5%，截至发稿，股价上涨4.16%，现报75.10港元，成交额4.38亿港元。国货美妆头部品牌可复美近日深陷“EGF添加门”舆论漩涡。陕西省药监局针对近日媒体对可复美品牌“检出违禁添加表皮生长因子EGF”的报道做出通报，多批次可复美产品均未检出EGF。据悉，可复美为巨子生物的核心品牌，2024年销售收入达45.42亿元，同比增长62.9%，占公司总营收的82%。尽管如此，巨子生物的盈利前景依然稳健。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042212232894dd9fea&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042212232894dd9fea&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1207","LU2488822045.USD","SG9999004311.SGD","02367"],"gpt_icon":0},{"id":"2529039394","title":"港股异动 | 巨子生物(02367)早盘涨超5% 陕西省药监局通报多批次可复美产品均未检出EGF","url":"https://stock-news.laohu8.com/highlight/detail?id=2529039394","media":"智通财经网","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529039394?lang=zh_cn&edition=full","pubTime":"2025-04-22 11:29","pubTimestamp":1745292540,"startTime":"0","endTime":"0","summary":"巨子生物早盘涨超5%，截至发稿，涨4.44%，报75.3港元，成交额4.22亿港元。消息面上，国货美妆头部品牌可复美近日深陷“EGF添加门”舆论漩涡。陕西省药监局针对近日媒体对可复美品牌“检出违禁添加表皮生长因子EGF”的报道做出通报，多批次可复美产品均未检出EGF。据悉，可复美为巨子生物的核心品牌，2024年销售收入达45.42亿元，同比增长62.9%，占公司总营收的82%。尽管如此，巨子生物的盈利前景依然稳健。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-04-22/doc-inetzeny4301594.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1207","SG9999004311.SGD","LU2488822045.USD","EGF","02367"],"gpt_icon":0},{"id":"2529999493","title":"巨子生物盘中异动 早盘股价大涨5.06%报75.750港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2529999493","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529999493?lang=zh_cn&edition=full","pubTime":"2025-04-22 11:06","pubTimestamp":1745291164,"startTime":"0","endTime":"0","summary":"2025年04月22日早盘11时06分，巨子生物股票出现异动，股价急速拉升5.06%。截至发稿，该股报75.750港元/股，成交量462万股，换手率0.45%，振幅4.51%。资金方面，该股资金流入1.70393亿港元，流出1.09441亿港元。巨子生物股票所在的生物技术行业中，整体涨幅为3.64%。上市不到3年，巨子生物已公告两次配售，融资总金额近40亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422110605a461dd8c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422110605a461dd8c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02367","LU2488822045.USD","SG9999004311.SGD","BK1207"],"gpt_icon":0},{"id":"2529557843","title":"不差钱的巨子生物连续高位融资，主力产品遭投诉","url":"https://stock-news.laohu8.com/highlight/detail?id=2529557843","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529557843?lang=zh_cn&edition=full","pubTime":"2025-04-21 12:08","pubTimestamp":1745208515,"startTime":"0","endTime":"0","summary":"近日，巨子生物（02367）推出再融资计划后，股价应声下跌。4月17日早间，巨子生物发布公告称，公司与补足卖方及联席账簿管理人订立配售及认购协议，拟以每股66.65港元的价格配售3500万股现有股份，并通过补足认购同等数量新股份，预计募集资金总额约23.33亿港元，净额约22.94亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504213382733773.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02367","SG9999004311.SGD","BK1207","LU2488822045.USD"],"gpt_icon":0},{"id":"2528075772","title":"巨子生物旗下可复美检出违禁成分？陕西省药监局通报","url":"https://stock-news.laohu8.com/highlight/detail?id=2528075772","media":"南方都市报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528075772?lang=zh_cn&edition=full","pubTime":"2025-04-19 16:20","pubTimestamp":1745050800,"startTime":"0","endTime":"0","summary":"近日，巨子生物旗下护肤品牌可复美被消费者投诉含有违禁成分EGF一事引起热议。4月12日，可复美官方发布声明称，公司已委托两家专业检测机构分别采用两种检测方法对同批次产品独立检测，均未检出EGF。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250419162627973d6ae4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250419162627973d6ae4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1207","LU2488822045.USD","02367","SG9999004311.SGD"],"gpt_icon":0},{"id":"2528707106","title":"主品牌深陷EGF添加门 巨子生物业绩或将面临剧烈波动- DoNews","url":"https://stock-news.laohu8.com/highlight/detail?id=2528707106","media":"iDoNews","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528707106?lang=zh_cn&edition=full","pubTime":"2025-04-18 10:02","pubTimestamp":1744941734,"startTime":"0","endTime":"0","summary":"然而，高增长表象下仍有隐忧，重营销轻研发、主品牌依赖与同质化竞争使得巨子生物高增长存疑。单一品牌依赖风险加剧，一旦可复美因市场竞争或质量问题受挫，公司整体业绩将面临剧烈波动。业内认为，若无法降低品牌依赖、提升研发投入突破技术瓶颈，巨子生物高增长神话或将面临终结。这场“EGF添加门”事件，不仅是对巨子生物产品质量的拷问，更是对其商业模式可持续性的深刻反思。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250418100513973bfb06&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250418100513973bfb06&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02367","SG9999004311.SGD","LU2488822045.USD","BK1207"],"gpt_icon":0},{"id":"2528871147","title":"每日卖空追踪 | 巨子生物 04月17日卖空量成交184.6万股，卖空比例为3.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2528871147","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528871147?lang=zh_cn&edition=full","pubTime":"2025-04-17 20:29","pubTimestamp":1744892987,"startTime":"0","endTime":"0","summary":"巨子生物北京时间04月17日，跌2.1%，卖空量成交184.6万股，较上一交易日增加272.18%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250417202951a6bdf8a5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250417202951a6bdf8a5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1207","LU2488822045.USD","02367","SG9999004311.SGD"],"gpt_icon":0},{"id":"2528796428","title":"北水动向|北水成交净买入23.09亿 北水继续加仓科网股 全天抛售小米(01810)超13亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2528796428","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528796428?lang=zh_cn&edition=full","pubTime":"2025-04-17 17:50","pubTimestamp":1744883448,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，4月17日港股市场，北水成交净买入23.09亿港元，其中港股通(沪)成交净买入5.08亿港元，港股通(深)成交净买入18.01亿港元。北水净卖出最多的个股是盈富基金、小米集团-W、中海油。北水重新加仓芯片股。小米集团-W遭净卖出13.42亿港元。4月14日，小米集团核心子公司小米通讯200亿元公司债项目状态更新为“提交注册”。此外有媒体报道称，小米原定于4月底举行的2025年投资者日因故延期至6月3日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1280176.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1023057109.AUD","LU1993786604.SGD","LU2226246903.HKD","LU0593848301.USD","LU1868837565.USD","LU0797268264.HKD","LU2097828474.EUR","LU0348783233.USD","XIACY","89988","LU0307460666.USD","BK1207","LU0054450605.USD","SG9999002950.SGD","LU0132412106.USD","LU1981816686.USD","LU0084288322.USD","LU0823413660.USD","LU0264606111.USD","LU0499858438.USD","LU0348784397.USD","HXXD.SI","LU0048580855.USD","LU2087589342.USD","IE00B543WZ88.USD","BK1502","LU2097828805.USD","LU1188198961.HKD","LU0572944931.SGD","LU1880383440.USD","LU0140636845.USD","LU0516422952.EUR","LU0228659784.USD","LU1515016050.SGD","LU0229945570.USD","81810","01810","LU0348805143.USD","LU0642271901.SGD","LU0211977185.USD","LU2097828631.EUR","LU0611395673.USD","LU0737861699.HKD","02367","LU0128522157.USD","LU2488822045.USD","HBBD.SI"],"gpt_icon":1},{"id":"2528164768","title":"花旗：维持巨子生物“买入”评级 目标价78.1港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2528164768","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528164768?lang=zh_cn&edition=full","pubTime":"2025-04-17 15:33","pubTimestamp":1744875180,"startTime":"0","endTime":"0","summary":"巨子生物周四早上公布，配售最多3,500万股股份，相当于扩大后股本3.27%;配售价66.65港元，较上交易日收市价折让9.5%。花旗发布研报称，鉴于较大的折让，预期短期内该股的股价将会承压。尽管如此，巨子生物的盈利前景依然稳健，故维持该股的“买入”评级，目标价78.1港元。巨子生物表示，集资主要用于海外业务发展，因其现金大部分在中国境内。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250417153718973aec18&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250417153718973aec18&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02367"],"gpt_icon":0},{"id":"2528757097","title":"花旗：维持巨子生物(02367)“买入”评级 目标价78.1港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2528757097","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528757097?lang=zh_cn&edition=full","pubTime":"2025-04-17 15:16","pubTimestamp":1744874161,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，花旗发布研报称，鉴于较大的折让，预期短期内该股的股价将会承压。尽管如此，巨子生物(02367)的盈利前景依然稳健，故维持该股的“买入”评级，目标价78.1港元。巨子生物周四(17日)早上公布，配售最多3,500万股股份，相当于扩大后股本3.27%;配售价66.65港元，较上交易日(16日)收市价折让9.5%。集资总额23.33亿港元，所得净额22.94亿港元，配售及认购所得款项净额拟用于核心业务的发展及生态圈布局，包括品牌推广、市场营销、品类扩展、海外业务及研发投入;以及补充流动资金及作一般企业用途。巨子生物表示，集资主要用于海外业务发展，因其现金大部分在中国境内。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1280014.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02367"],"gpt_icon":0},{"id":"2528751270","title":"巨子生物，拟配售融资逾23亿，上市以来再融资超IPO募资额7倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2528751270","media":"市场资讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528751270?lang=zh_cn&edition=full","pubTime":"2025-04-17 14:10","pubTimestamp":1744870247,"startTime":"0","endTime":"0","summary":"较昨日收市价73.65港元折让9.5%，配售股份占扩大后股本约3.27%。巨子生物，于2022年11月4日在港交所主板上市，当时募资约5.49亿港元。计及此次配售，巨子生物自香港上市以来已有两次再融资配售，再融资金额合计将近40亿港元，是其IPO募资额的7.23倍。截至午间收市，巨子生物每股报70.75港元，总市值约732.90亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250417141054973ad7b3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250417141054973ad7b3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02367","LU2488822045.USD","BK1207","SG9999004311.SGD"],"gpt_icon":0},{"id":"2528780986","title":"巨子生物启动配售及认购计划 拟募资逾23亿港元加码核心业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2528780986","media":"财中社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528780986?lang=zh_cn&edition=full","pubTime":"2025-04-17 10:08","pubTimestamp":1744855721,"startTime":"0","endTime":"0","summary":"巨子生物（02367）于2025年4月17日公告，公司与补足卖方及联席账簿管理人订立配售及认购协议，拟以每股66.65港元的价格配售3500万股现有股份，并通过补足认购同等数量新股份，预计募集资金总额约23.33亿港元，净额约22.94亿港元。根据公告，此次配售价较4月16日收盘价73.65港元折让约9.50%，较前五个交易日平均价71.50港元折让6.78%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504173379669072.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2488822045.USD","BK1207","02367","SG9999004311.SGD"],"gpt_icon":0},{"id":"2528118782","title":"巨子生物盘中异动 早盘股价大跌9.03%报67.000港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2528118782","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528118782?lang=zh_cn&edition=full","pubTime":"2025-04-17 09:30","pubTimestamp":1744853407,"startTime":"0","endTime":"0","summary":"2025年04月17日早盘09时30分，巨子生物股票出现异动，股价大幅下跌9.03%。截至发稿，该股报67.000港元/股，成交量3685.22万股，换手率3.56%，振幅1.83%。资金方面，该股资金流入1124.15万港元，流出3084.69万港元。巨子生物股票所在的生物技术行业中，整体跌幅为1.15%。对于产品涉嫌添加该违禁成分，4月12日，可复美公开回应称“旗下包括此产品在内的所有产品均未添加人表皮生长因子”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250417093007a6bd3ddd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250417093007a6bd3ddd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SG9999004311.SGD","BK1207","02367","LU2488822045.USD"],"gpt_icon":0},{"id":"2528782817","title":"港股异动 | 巨子生物(02367)低开逾7% 公司拟折让约9.5%先旧后新配股 净筹近23亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2528782817","media":"智通财经网","labels":["shareholding","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528782817?lang=zh_cn&edition=full","pubTime":"2025-04-17 09:23","pubTimestamp":1744852980,"startTime":"0","endTime":"0","summary":"巨子生物早盘低开逾7%，截至发稿，跌7.67%，报68港元，成交额24.14亿港元。消息面上，巨子生物宣布，先旧后新配售3500万股，占扩大后股本3.27%，每股配售价66.65港元，较上一日收盘价73.65港元折让9.5%，所得款项净额预期合共约为22.94亿港元，拟用于核心业务的发展及生态圈布局，包括但不限于品牌推广、市场营销、品类扩展、海外业务及研发投入；及补充流动资金及作一般企业用途。认购股份将根据一般授权配发及发行。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-04-17/doc-inetmqpy6127616.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,movement","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02367","LU2488822045.USD","BK1207","SG9999004311.SGD"],"gpt_icon":0},{"id":"2528786160","title":"【券商聚焦】中信证券指我国化妆品市场进入稳增长阶段 但格局与日本存在显著差异","url":"https://stock-news.laohu8.com/highlight/detail?id=2528786160","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528786160?lang=zh_cn&edition=full","pubTime":"2025-04-17 08:57","pubTimestamp":1744851432,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券表示，日本化妆品百年发展中经济与需求演替伴随前行，80年代前经济高增加速行业扩容，80年代后行业降速、需求特征孕育结构性机遇，其中：①产品价格分化，高端需求长期平稳，大众品性价比提升催生功效妆品；②渠道受性价比驱动演变，药妆店以药带货实现低价胜出。当前，我国化妆品市场环境与日本1980s后存在一定相似性，市场规模同样进入稳增长阶段，且在消费者偏好、产品定位端表现出与日本相似的性价比、功效护肤特征。但我国化妆品市场格局与日本存在显著差异，头部市场长期由外资品牌主导；而国货品牌更加匹配当前消费者对质价比、功效护肤的需求，有望在竞争格局维度受益于市场需求的变化。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/MWIyNWQwZjQ4NTQyNjI4OTI5NDE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWIyNWQwZjQ4NTQyNjI4OTI5NDE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1957355","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["600030","LU1655091616.SGD","LU1064130708.USD","BK1147","BK0183","BK0188","LU1997245177.USD","LU0405327494.USD","LU1328615791.USD","LU2148510915.USD","BK0276","LU1997245094.SGD","LU0405327148.USD","LU1997244956.HKD","06030","LU1794554557.SGD","LU2488822045.USD","BK0028","LU1720050803.USD","02145","SG9999004311.SGD","LU1064131003.USD","BK1516","BK1564","LU2495084118.USD","LU2289578879.USD","BK1207","BK0012","BK1521","02367","BK0196"],"gpt_icon":0},{"id":"2528202417","title":"巨子生物：根据一般授权配售现有股份及补足认购新股份 募资约23亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2528202417","media":"格隆汇","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528202417?lang=zh_cn&edition=full","pubTime":"2025-04-17 06:49","pubTimestamp":1744843740,"startTime":"0","endTime":"0","summary":"配售股份数目应与认购股份数目相同，约占本公告日期公司已发行股份数目的约3.38%，及经配发及发行认购股份扩大后的股份数目的约3.27%。配售及认购所得款项总额预期合共约为23.33亿港元，而配售及认购所得款项净额预期合共约为22.94亿港元。配售及认购亦将透过吸引若干高品质机构投资者进一步丰富公司股东基础，并且通过配售进一步加强股份流动性。认购股份将根据一般授权配发及发行。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041706524394d7e831&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041706524394d7e831&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SG9999004311.SGD","LU2488822045.USD","BK1207","02367"],"gpt_icon":0},{"id":"2528201260","title":"巨子生物(02367)拟折让约9.50%先旧后新配股 最高净筹约22.94亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2528201260","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528201260?lang=zh_cn&edition=full","pubTime":"2025-04-17 06:17","pubTimestamp":1744841848,"startTime":"0","endTime":"0","summary":"智通财经APP讯，巨子生物 公布，于2025年4月16日，该公司、补足卖方及联席账簿管理人订立配售及认购协议，据此，补足卖方已同意出售所持有的3500万股股份，每股配售价66.65港元;该公司有条件同意向补足卖方发行有关数目的新股份，每股配售价66.65港元。配售价每股66.65港元较2025年4月16日收市价每股股份73.65港元折让约9.50%，配售及认购所得款项总额预期合共约为23.33亿港元，而配售及认购所得款项净额预期合共约为22.94亿港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1279827.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2488822045.USD","02367","BK1207","SG9999004311.SGD"],"gpt_icon":1},{"id":"2527950219","title":"每日卖空追踪 | 巨子生物 04月16日卖空量成交49.6万股，卖空比例为6.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2527950219","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527950219?lang=zh_cn&edition=full","pubTime":"2025-04-16 20:18","pubTimestamp":1744805933,"startTime":"0","endTime":"0","summary":"巨子生物北京时间04月16日，跌3.35%，卖空量成交49.6万股，较上一交易日减少60.6%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416201857a45b1bdc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416201857a45b1bdc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SG9999004311.SGD","LU2488822045.USD","02367","BK1207"],"gpt_icon":0},{"id":"2527525825","title":"可复美陷产品添加表皮生长因子“罗生门”","url":"https://stock-news.laohu8.com/highlight/detail?id=2527525825","media":"中国新闻网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527525825?lang=zh_cn&edition=full","pubTime":"2025-04-16 15:07","pubTimestamp":1744787232,"startTime":"0","endTime":"0","summary":"中新网北京4月15日电 近日，有消费者向媒体控诉可复美在一款产品中添加了表皮生长因子。目前，双方的争执点在于：可复美产品中是否有表皮生长因子，且双方均有相关检测结果支持各自的观点。秦女士还发现，这款产品在国家药品监督管理局备案中也并未显示有表皮生长因子成分。对于产品涉嫌添加该违禁成分，4月12日，可复美公开回应称“旗下包括此产品在内的所有产品均未添加人表皮生长因子”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041615071897399375&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041615071897399375&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02367","BK1207","LU2488822045.USD","SG9999004311.SGD"],"gpt_icon":0},{"id":"2527400305","title":"巨子生物盘中异动 早盘股价大跌5.05%报72.350港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2527400305","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527400305?lang=zh_cn&edition=full","pubTime":"2025-04-16 10:05","pubTimestamp":1744769104,"startTime":"0","endTime":"0","summary":"2025年04月16日早盘10时05分，巨子生物股票出现波动，股价快速下跌5.05%。截至发稿，该股报72.350港元/股，成交量206.12万股，换手率0.20%，振幅5.18%。资金方面，该股资金流入3249.64万港元，流出7242.24万港元。巨子生物股票所在的生物技术行业中，整体跌幅为1.51%。2022年，巨子生物登陆港交所，成为“重组胶原蛋白第一股”。2022年，敷尔佳研发费用为1542.61万元，仅占营业收入的0.87%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416100505a6bbf081&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416100505a6bbf081&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1207","SG9999004311.SGD","02367","LU2488822045.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xajuzi.com","stockEarnings":[{"period":"1week","weight":0.0059},{"period":"1month","weight":0.1013},{"period":"3month","weight":0.4},{"period":"6month","weight":0.4194},{"period":"1year","weight":0.6435},{"period":"ytd","weight":0.5361}],"compareEarnings":[{"period":"1week","weight":0.0045},{"period":"1month","weight":-0.0898},{"period":"3month","weight":0.0902},{"period":"6month","weight":0.0524},{"period":"1year","weight":0.3059},{"period":"ytd","weight":0.0749}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"巨子生物控股有限公司是一家中国的投资控股公司。该公司通过其子公司主要从事基于生物活性材料的美容和健康产品的研发、生产和销售。该公司的主要产品包括功能性护肤品和医用敷料，其产品的关键生物活性成分为重组胶原蛋白。该公司还开发和生产基于人参皂苷技术的稀有功能食品。该公司主要在国内市场开展其业务。","exchange":"SEHK","name":"巨子生物","nameEN":"GIANT BIOGENE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"巨子生物(02367)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供巨子生物(02367)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"巨子生物,02367,巨子生物股票,巨子生物股票老虎,巨子生物股票老虎国际,巨子生物行情,巨子生物股票行情,巨子生物股价,巨子生物股市,巨子生物股票价格,巨子生物股票交易,巨子生物股票购买,巨子生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"巨子生物(02367)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供巨子生物(02367)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}